These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11721173)

  • 1. Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment.
    Gerber B; Krause A; Markmann S; Reimer T; Fietkau R; Müller H
    Oncology; 2001; 61(4):271-4. PubMed ID: 11721173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
    Horton JK; Halle J; Ferraro M; Carey L; Moore DT; Ollila D; Sartor CI
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):998-1004. PubMed ID: 19560883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
    Cook-Bruns N
    Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
    Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
    Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
    Haq B; Geyer CE
    Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure.
    Walji N; Bhatt L; Dhallu S; Fernando IN
    Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
    Láng I; Hitre E
    Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab in the treatment of advanced breast cancer: single-center experience.
    Mrsić M; Grgić M; Budisić Z; Podolski P; Bogdanić V; Labar B; Jakić-Razumović J; Restek-Samarzija N; Gosev M
    Ann Oncol; 2001; 12 Suppl 1():S95-6. PubMed ID: 11521730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.